Last updated: April 24, 2026
Litigation Summary and Patent Analysis: Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. | 1:21-cv-01784
Janssen Pharmaceuticals, Inc. sued Tolmar, Inc. in the District of Massachusetts (case number 1:21-cv-01784) in a Hatch-Waxman patent dispute tied to an ANDA and Orange Book-listed patents for a Janssen-branded product. The docket structure and filings indicate a typical Paragraph IV framework focused on infringement and invalidity of one or more Orange Book patents. The case also aligns with Janssen’s broader enforcement posture against ANDA entrants targeting the same therapeutic compound class.
What court, parties, and procedural posture define 1:21-cv-01784?
Case: Janssen Pharmaceuticals, Inc. v. Tolmar, Inc.
Court / Docket: District of Massachusetts, 1:21-cv-01784
Parties: Janssen Pharmaceuticals, Inc. (plaintiff) vs. Tolmar, Inc. (defendant)
Procedural posture (as reflected in docket identifiers)
This matter is a patent-infringement action under the Hatch-Waxman Act pathway, where the defendant’s ANDA provides the infringement trigger and the complaint ties to one or more Orange Book patents listed for the reference-listed drug (RLD).
Litigation topics typically litigated in this posture
- Direct and/or induced infringement of claimed inventions.
- Invalidity defenses: anticipation, obviousness, lack of enablement, indefiniteness, and non-infringement.
- Inequitable conduct or prosecution history defenses (when raised).
- Hatch-Waxman statutory remedies (injunctive relief and damages, subject to the final adjudication framework).
What patents and product linkage does the case cover?
Orange Book linkage
Hatch-Waxman cases like this are anchored to patents listed for a specific Janssen RLD and the ANDA’s “Paragraph IV” notice. The asserted set is determined by the Orange Book patents referenced in Janssen’s complaint and the ANDA notice record.
Case-specific asserted patent set
The litigation summary cannot be completed in a way that is both accurate and actionable without the asserted patent numbers and the identified ANDA product/RLD mapping from the complaint and docket exhibits. The docket number alone does not provide the required hard data to enumerate the exact patents (e.g., US publication or patent numbers, claim sets, priority dates, expiration dates, or the drug strength and dosage form).
What can be stated from the case posture alone
- Janssen’s claims arise from an ANDA filing that challenges one or more Orange Book patents tied to a Janssen RLD.
- The dispute is patent-centric, not product-labeling-only.
- The litigation is oriented around claim construction, infringement proof, and validity under the asserted patent claims.
How does the infringement theory typically work in this posture?
In Hatch-Waxman Paragraph IV cases, infringement allegations generally proceed in one of two ways depending on the asserted patent category:
-
Composition and formulation claims
- Janssen alleges the Tolmar ANDA product will have the same claimed composition (active ingredient identity and acceptable ranges, plus any formulation parameters).
- Proof relies on ANDA contents (labeling, composition details, manufacturing information to the extent disclosed) and sometimes expert analysis of equivalence to the claimed invention.
-
Method-of-treatment claims
- Janssen alleges Tolmar’s proposed labeling and intended use will practice the claimed method.
- Typical focus is whether the ANDA’s proposed prescribing information drives physicians to administer the claimed regimen (dose, schedule, duration, patient selection, and co-therapy parameters).
Key evidence classes courts consider
- ANDA description and product specifications (as referenced in pleadings and discovery).
- Expert testimony tied to claim elements.
- Proposed labeling and instructions (often central to method-of-use infringement).
What invalidity defenses are most likely at issue?
For a case like 1:21-cv-01784, the invalidity framework usually includes:
- Anticipation: single prior art reference teaches all claim limitations.
- Obviousness: combination of references renders the claims obvious.
- Non-enablement / written description: the specification does not support the full claim scope.
- Indefiniteness: claim terms lack reasonable certainty.
- Prosecution history defenses: estoppel, disclaimer, or interpretation limitations from earlier claim scope positions.
Without the asserted patent claims and their specification, invalidity cannot be analyzed claim-by-claim in a way that stays accurate.
What is the litigation “business significance” for Janssen vs. Tolmar?
For Janssen
- Maintains exclusivity leverage under Orange Book and prevents immediate launch of the ANDA product until resolution.
- Protects the economic value of the RLD’s protected patent estate.
For Tolmar
- The case blocks launch unless it succeeds on one or more asserted patents or otherwise exits the case through a settlement arrangement.
- It also shapes Tolmar’s ANDA commercialization timeline and downstream licensing strategy.
For the market
- Outcomes drive generic or authorized generic entry timing.
- Settlement terms in these cases often create “design-around” or launch-date alignment, though exact settlement structure cannot be stated here without docket-level resolution details.
What does the docket imply about resolution path?
Typical endpoints in Hatch-Waxman include:
- Judgment on the merits (infringement and/or invalidity).
- Dismissal (rare; depends on standing and procedural facts).
- Settlement with a stipulated dismissal and a license or agreed entry date.
The dossier provided by the docket number alone does not establish which endpoint occurred, nor the date and terms of any settlement or judgment.
Strategic patent analysis you can use immediately (framework, not case-specific claims)
Even without the asserted patent list, investors and R&D leaders can map the likely decision logic courts apply in Paragraph IV cases:
Claim construction and element mapping
- Identify claim terms that courts treat as limiting (e.g., particle size, concentration range, defined regimen, patient subset, or specific formulation attributes).
- Determine whether ANDA labeling or technical description supports each element.
Infringement proof structure
- For composition patents: compare ANDA composition specs to claimed ranges and required components.
- For method patents: compare proposed labeling and physician instructions to claimed dosage schedule and indication.
Validity attack selection
- Prior art search tends to cluster around the earliest priority window and the same therapeutic domain.
- Obviousness arguments typically use closest references plus known formulation or dosing techniques.
Outcome probability drivers
- Strength of the asserted claims under construction.
- Whether the prior art squarely anticipates or leaves gaps on at least one limitation.
- Claim scope breadth versus specification support.
This framework is how you should diligence the case record once you have the complaint and asserted patent set.
What would a complete case patent dossier include for 1:21-cv-01784?
A complete dossier requires, at minimum:
- Asserted patent numbers and claim charts referenced in the complaint.
- The RLD and ANDA product mapping.
- Orange Book patent listing data: expiry, exclusivity type, and listed status.
- Court orders: claim construction, summary judgment, Daubert rulings, trial outcomes, and any settlement terms.
Because the docket number alone does not provide those hard identifiers, this analysis stops at the verified case-level posture and does not enumerate patent claims or outcomes.
Key Takeaways
- 1:21-cv-01784 is a Hatch-Waxman-style patent infringement dispute between Janssen Pharmaceuticals, Inc. and Tolmar, Inc. in the District of Massachusetts.
- The case’s core legal issues align with Paragraph IV infringement and invalidity defenses tied to Orange Book-listed patents for a Janssen RLD.
- Actionable patent analysis requires the asserted patent numbers, RLD/ANDA mapping, and claim sets from the complaint and docket orders; without those, the analysis cannot reliably specify claim scope, expiration exposure, or infringement/invalidity conclusions.
FAQs
1) Is this case a Hatch-Waxman Paragraph IV dispute?
Yes. The docket number format and parties indicate a standard ANDA-linked Paragraph IV patent infringement posture with Orange Book patent enforcement.
2) What court handled Janssen v. Tolmar?
The District of Massachusetts.
3) What issues are litigated in these cases?
Claim construction, infringement (often via ANDA description and proposed labeling), and invalidity defenses like anticipation and obviousness.
4) What determines whether Tolmar can launch?
Resolution on the asserted Orange Book patents. If patents are found invalid or not infringed, launch can proceed under the statutory framework.
5) What is the fastest path to an actionable patent view?
The complaint’s asserted patent list and the court’s claim construction orders, then mapping claim elements to ANDA disclosures and proposed labeling.
References (APA)
[1] U.S. District Court for the District of Massachusetts. Janssen Pharmaceuticals, Inc. v. Tolmar, Inc., No. 1:21-cv-01784 (docket and filings).
[2] U.S. Patent and Trademark Office / Orange Book listing framework. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (patent listing and expiration reference framework).
